Carbocyclic nucleoside analogs

Claim 2

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 1 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and R s are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 1 o alkyl; and wherein M is hydrogen, C 1 to C 1 o alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are as defined above, or -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 1 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 R 1 R 2 wherein R 1 and R 2 are as defined above; and wherein E is hydrogen, -CH 2 OH or -OH; and G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -CH 2 0H, -CH 2 OR 20 wherein R 20 is C 1 to C 6 alkyl, -CH 2 OC(O)R 21 , wherein R 21 is C 1 to C 10 alkyl, -CH 3 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )-(NH 2 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 l, -C(O)H, -CH 2 CN. -CH 2 N 3 , -CH 2 NR 1 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 OR 20 wherein R 20 is as defined above, -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 0P0 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 1 , R 2 and R 3 are as defined above, with the proviso that when E is -OH then D is not -OH and with the proviso that when E is hydrogen and D is hydrogen or C 1 to C 1 0 alkyl then G is not hydrogen or C 1 to C 10 alkyl; or a pharmaceutically acceptable salt thereof.

Claim 3

The compound of Claim 1 wherein G is -CH 2 0H; D is -CH 2 OH; A is wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are independently selected from hydrogen and C 1 to C 10 o alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and R 5 are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , Rg and R 10 are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 10 alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; or A is wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are as defined above, -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 1 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R 1 and R 2 are as defined above.

Claim 4

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R io are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 1 alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarbonyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are as defined above, or -NHC(0)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R, and R 2 are as defined above; and wherein E is hydrogen, -CHzOH or -OH; and G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -CH 2 OH, -CH 2 OR 20 wherein R 20 is C 1 to C 6 alkyl, -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )-(NH 2 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br. -CH 2 l, -C(O)H, CH 2 CN, -CH 2 N 3 , -CH 2 NR 1 R 2 . -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 20 wherein R 20 is as defined above, -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 0P0 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 C0 2 R 3 wherein R 1 , R 2 and R 3 are as defined above; with the proviso that when E is -OH then D is not -OH and with the proviso that when E is hydrogen and D is hydrogen or C 1 to C 1 o alkyl then G is not hydrogen or C 1 to C 10 alkyl; and with the proviso that when E is hydrogen and G is -OH, then D is other than -CH 2 0H, -CH 2 OC(O)R 21 or -CH 2 OPO 3 H 2 or a pharmaceutically acceptable salt thereof.

Claim 5

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R io are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 1 alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarbonyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are as defined above, or -NHC(0)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R, and R 2 are as defined above; and wherein E is hydrogen, -CHzOH or -OH; and G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -CH 2 OH, -CH 2 OR 20 wherein R 20 is C 1 to C 6 alkyl, -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )-(NH 2 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br. -CH 2 l, -C(O)H, CH 2 CN, -CH 2 N 3 , -CH 2 NR 1 R 2 . -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 20 wherein R 20 is as defined above, -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 0P0 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 C0 2 R 3 wherein R 1 , R 2 and R 3 are as defined above; with the proviso that when E is -OH then D is not -OH and with the proviso that when E is hydrogen and D is hydrogen or C 1 to C 1 o alkyl then G is not hydrogen or C 1 to C 10 alkyl; and with the proviso that when E is hydrogen and G is -OH, then D is other than -CH 2 0H, -CH 2 OC(O)R 21 or -CH 2 OPO 3 H 2 or a pharmaceutically acceptable salt thereof.

Claim 6

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 8 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 10 -alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is O or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are as defined above, or -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 R 1 R 2 wherein R 1 and R 2 are as defined above; and wherein E is hydrogen; and G is -OH and D is -CH 2 0H, -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C io alkyl or -CH 2 OPO 3 H 2 ; or a pharmaceutically acceptable salt thereof.

Claim 7

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 8 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 10 -alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is O or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are as defined above, or -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R, and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 R 1 R 2 wherein R 1 and R 2 are as defined above; and wherein E is hydrogen; and G is -OH and D is -CH 2 0H, -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C io alkyl or -CH 2 OPO 3 H 2 ; or a pharmaceutically acceptable salt thereof.

Claim 8

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 . and R 5 are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 1 o alkyl; and wherein M is hydrogen, C 1 to C 10 alkyl, halogen, wherein m is 1 to 5, or -NR1 R 2 wherein R, and R 2 are as defined above; and Z is hydrogen halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yi group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are as defined above, or -NHC(0)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxymethyl, -NR 1 R 2 wherein R 1 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R, and R 2 are as defined above; and wherein E is hydrogen, -CH 2 0H or -OH; and G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -CH 2 0H, -CH 2 0R 20 wherein R 20 is C 1 to C 6 alkyl, -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl -CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )-(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, CH 2 l, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 1 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 R 20 wherein R 20 is as defined above, -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -OCH 2 P0 3 H 2 and -CH 2 C0 2 R 3 wherein R 1 , R 2 and R 3 are as defined above, with the proviso that when E is -OH then D is not -OH and with the proviso that when E is hydrogen and D is hydrogen or C 1 to C 1 o alkyl then G is not hydrogen or C 1 to C 10 alkyl and with the proviso that when E is hydrogen and D is -CH 2 0H, -CH 2 0P0 3 H 2 or -CH 2 0C-(O)R 21 then G is other than -CH 2 0H, -CH 2 0P0 3 H 2 or -CH 2 0C(O)R 21 or when E is hydrogen and G is -CH 2 0H, -CH 2 OPO 3 H 2 or -CH 2 OC(O)R 2 , then D is other than -CH 2 0H, -CH 2 OPO 3 H 2 or -CH 2 0C(O)R 21 ; or a pharmaceutically acceptable salt thereof.

Claim 9

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N=CHNR 4 R 5 wherein R 4 . and R 5 are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein R 6 and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 1 o alkyl; and wherein M is hydrogen, C 1 to C 10 alkyl, halogen, wherein m is 1 to 5, or -NR1 R 2 wherein R, and R 2 are as defined above; and Z is hydrogen halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yi group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are as defined above, or -NHC(0)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxymethyl, -NR 1 R 2 wherein R 1 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R, and R 2 are as defined above; and wherein E is hydrogen, -CH 2 0H or -OH; and G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -CH 2 0H, -CH 2 0R 20 wherein R 20 is C 1 to C 6 alkyl, -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl -CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )-(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, CH 2 l, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 1 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 R 20 wherein R 20 is as defined above, -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -OCH 2 P0 3 H 2 and -CH 2 C0 2 R 3 wherein R 1 , R 2 and R 3 are as defined above, with the proviso that when E is -OH then D is not -OH and with the proviso that when E is hydrogen and D is hydrogen or C 1 to C 1 o alkyl then G is not hydrogen or C 1 to C 10 alkyl and with the proviso that when E is hydrogen and D is -CH 2 0H, -CH 2 0P0 3 H 2 or -CH 2 0C-(O)R 21 then G is other than -CH 2 0H, -CH 2 0P0 3 H 2 or -CH 2 0C(O)R 21 or when E is hydrogen and G is -CH 2 0H, -CH 2 OPO 3 H 2 or -CH 2 OC(O)R 2 , then D is other than -CH 2 0H, -CH 2 OPO 3 H 2 or -CH 2 0C(O)R 21 ; or a pharmaceutically acceptable salt thereof.

Claim 10

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N = CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein Rs and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 10 alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are as defined above, or -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R 1 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R 1 and R 2 are as defined above; and wherein E is hydrogen; and G and D are independently selected from -CH 2 0H, -CH 2 0P0 3 H 2 and -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C 10 alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that the compound is not 1-(2,3-bis(hydroxymethyl)cyclobutyl)uracil or 9-(2,3-bis(hydroxymethyl)cyclobutyl)hypoxanthine.

Claim 11

A compound of the formula: wherein A is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group selected from the group consisting of and wherein J and L are independently selected from hydrogen, -OH, halogen, alkoxy, -SH, thioalkoxy, -N 3 , wherein m is 1 to 5, -NR 1 R 2 wherein R 1 and R 2 are independently selected from hydrogen and C 1 to C 10 alkyl, -NHC(O)R 3 wherein R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, -N = CHNR 4 R 5 wherein R 4 and Rs are independently selected from C 1 to C 10 alkyl, -N(R 6 )OR 7 wherein Rs and R 7 are independently selected from hydrogen and C 1 to C 10 alkyl, and -N(R 8 )NR 9 R 10 wherein R 8 , R 9 and R 10 are independently selected from hydrogen and C 1 to C 10 alkyl; and wherein M is hydrogen, C 1 to C 10 alkyl, halogen, wherein m is 1 to 5, or -NR 1 R 2 wherein R 1 and R 2 are as defined above; and Z is hydrogen, halogen, formyl, carboxyl, alkoxycarboyl, carboxamido or cyano; or A is a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group selected from the group consisting of and wherein V is 0 or S; Q is -OH, -SH, alkoxy, thioalkoxy, halogen, wherein m is 1 to 5, -NR 1 R 2 wherein R, and R 2 are as defined above, or -NHC(O)R 3 wherein R 3 is as defined above; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 1 R 2 wherein R 1 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 1 R 2 wherein R 1 and R 2 are as defined above; and wherein E is hydrogen; and G and D are independently selected from -CH 2 0H, -CH 2 0P0 3 H 2 and -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C 10 alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that the compound is not 1-(2,3-bis(hydroxymethyl)cyclobutyl)uracil or 9-(2,3-bis(hydroxymethyl)cyclobutyl)hypoxanthine.

Claim 12

9-(2,3-Bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 13

9-(2,3-Bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 14

9-(2,3-Bis(hydroxymethyl)cyclobutyl)adenine or a pharmaceutically acceptable salt thereof.

Claim 15

9-(2,3-Bis(hydroxymethyl)cyclobutyl)adenine or a pharmaceutically acceptable salt thereof.

Claim 16

A compound selected from the group consisting of 9-(2-(hydroxymethyl)-3-((phosphonyl)methoxy)-1 -cyclobutyl)guanine; 9-(2-(hydroxymethyl)-3-((phosphonyl)methoxy)-1 -cyclobutyl)adenine; 9-(3 -((phosphonyl)methoxy)cylcobutyl)guanine; 9-(3-((phosphonyl)methoxy)cyclobutyl)adenine. 1-(2,3-Bis(hydroxymethyl)cyclobutyl)cytosine; 9-(2',3'-Bis(acetoxymethyl)cyclobutyl)-2-aminopurine; 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)-2-aminopurine; and 9-(2',3'-Bis(acetoxymethyl)cyclobutyl)guanine; or a pharmaceutically acceptable salt thereof.

Claim 17

A compound selected from the group consisting of 9-(2-(hydroxymethyl)-3-((phosphonyl)methoxy)-1 -cyclobutyl)guanine; 9-(2-(hydroxymethyl)-3-((phosphonyl)methoxy)-1 -cyclobutyl)adenine; 9-(3 -((phosphonyl)methoxy)cylcobutyl)guanine; 9-(3-((phosphonyl)methoxy)cyclobutyl)adenine. 1-(2,3-Bis(hydroxymethyl)cyclobutyl)cytosine; 9-(2',3'-Bis(acetoxymethyl)cyclobutyl)-2-aminopurine; 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)-2-aminopurine; and 9-(2',3'-Bis(acetoxymethyl)cyclobutyl)guanine; or a pharmaceutically acceptable salt thereof.

Claim 18

An antiviral pharmaceutical composition comprising a pharmaceutical carrier and a pharmaceutically effective amount of a compound of Claim 1.

Claim 19

Use of a compound of Claim 1 for preparing a drug for treating or preventing a viral infection in a host in need of such treatment.

Claim 20

Use of 9-(2',3'-bis(hydroxymethyl)cyclobutyl) guanine or a pharmaceutically acceptable salt thereof, for preparing a drug for treating an HIV infection in a host in need of such treatment.

Claim 21

Use of 9-(2',3'-bis(hydroxymethyl)cyclobutyl) guanine or a pharmaceutically acceptable salt thereof, for preparing a drug for treating an HIV infection in a host in need of such treatment.

Claim 22

A pharmaceutical composition for treating an HIV infection comprising a pharmaceutical carrier and a pharmaceutically effective amount of 9-(2',3'-bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 23

A pharmaceutical composition for treating an HIV infection comprising a pharmaceutical carrier and a pharmaceutically effective amount of 9-(2',3'-bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 24

Use of 9-(2',3'-bis(hydroxymethyl)cycfobutyl) guanine or a pharmaceutically acceptable salt thereof, for preparing a drug for treating a hepatitis infection in a host in need of such treatment.

Claim 25

Use of 9-(2',3'-bis(hydroxymethyl)cycfobutyl) guanine or a pharmaceutically acceptable salt thereof, for preparing a drug for treating a hepatitis infection in a host in need of such treatment.

Claim 26

A pharmaceutical composition for treating a hepatitis infection comprising a pharmaceutical carrier and a pharmaceutically effective amount of 9-(3',3'-bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 27

A pharmaceutical composition for treating a hepatitis infection comprising a pharmaceutical carrier and a pharmaceutically effective amount of 9-(3',3'-bis(hydroxymethyl)cyclobutyl)guanine or a pharmaceutically acceptable salt thereof.

Claim 28

Use of a compound of Claim 1 for preparing a drug for treating a tumor in a host in need of such treatment.

Claim 29

An antitumor pharmaceutical composition comprising a pharmaceutical carrier and a pharmaceutically effective amount of a compound of Claim 1.

Claim 30

A compound of the formula: wherein Z is hydrogen, -CH 2 CH, -CH 2 OR 11 , -OH or -OR 11 ; and G and D are independently selected from hydrogen, C 1 to C, o alkyl, -OH, -OR 11 , -CH 2 OH, -CH 2 OR 11 , -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C 10 alkyl, -CH 2 OC(O)CH(R 22 ) (NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 ) (NH 12 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 CH, -CH 2 CI, -CH 2 F, -CH 2 BR, -CH 2 I. -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 OR 11 , -CH 2 CH 2 0C(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 0C(O)CH(R 22 ) (NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 P0 3 H 2 , -OCH 2 P0 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is hydrogen or an N-protecting group; with the proviso that when E is -OH then D is not -OH.

Claim 31

A compound of the formula: wherein Z is hydrogen, -CH 2 CH, -CH 2 OR 11 , -OH or -OR 11 ; and G and D are independently selected from hydrogen, C 1 to C, o alkyl, -OH, -OR 11 , -CH 2 OH, -CH 2 OR 11 , -CH 2 OC(O)R 2 , wherein R 21 is C 1 to C 10 alkyl, -CH 2 OC(O)CH(R 22 ) (NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 ) (NH 12 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 CH, -CH 2 CI, -CH 2 F, -CH 2 BR, -CH 2 I. -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 OR 11 , -CH 2 CH 2 0C(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 0C(O)CH(R 22 ) (NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 P0 3 H 2 , -OCH 2 P0 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is hydrogen or an N-protecting group; with the proviso that when E is -OH then D is not -OH.

Claim 32

A compound of the formula: wherein E is hydrogen, -CH 2 OH, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl -OH, -OR 11 , -CH 2 0H, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl -CH 2 0C(0)CH(R 22 )(NHRz 3 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 2 , wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R zz and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 P0 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkly or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is hydrogen or an N-protecting group; R 1 is hdyrogen, -NH 2 or -OH; R 17 is -OH or halogen; and R 1 is -N0 2 or -NH 2 ; with the proviso that when E is -OH then D is not -OH.

Claim 33

A compound of the formula: wherein E is hydrogen, -CH 2 OH, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl -OH, -OR 11 , -CH 2 0H, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl -CH 2 0C(0)CH(R 22 )(NHRz 3 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 OH, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 2 , wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R zz and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 P0 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkly or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is hydrogen or an N-protecting group; R 1 is hdyrogen, -NH 2 or -OH; R 17 is -OH or halogen; and R 1 is -N0 2 or -NH 2 ; with the proviso that when E is -OH then D is not -OH.

Claim 34

A compound of the formula: wherein E is hydrogen, -CH 2 0H, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -OR 11 , -CH 2 0H, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 21 , wherein R 21 is as defined above, -CH 2 CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 ar defined above -CH 2 CH 2 PO 3 H 2 , CH 2 0P0 3 H 2 , -CH 2 PO 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is an N-protecting group; and R 19 is C 1 to C 6 alkyl; with the proviso that when E is -OH then D is not -OH.

Claim 35

A compound of the formula: wherein E is hydrogen, -CH 2 0H, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -OR 11 , -CH 2 0H, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 OC(O)CH(R 22 )(NHR 23 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 21 , wherein R 21 is as defined above, -CH 2 CH 2 0C(O)CH(R 22 )(NHR 23 ) wherein R 22 and R 23 ar defined above -CH 2 CH 2 PO 3 H 2 , CH 2 0P0 3 H 2 , -CH 2 PO 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 12 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is an N-protecting group; and R 19 is C 1 to C 6 alkyl; with the proviso that when E is -OH then D is not -OH.

Claim 36

A compound of the formula: wherein E is hydrogen, -CH 2 OH, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -OR 11 , -CH 2 OH, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 0C(0)CH(R 22 )(NHRz 3 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 ) (NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 PO 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 2 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is an N-protecting group; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 12 R 2 wherein R 12 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 12 R 2 wherein R 12 and R 2 are as defined above; with the proviso that when E is -OH then D is not -OH.

Claim 37

A compound of the formula: wherein E is hydrogen, -CH 2 OH, -CH 2 OR 11 , -OH or -OR 11 ; G and D are independently selected from hydrogen, C 1 to C 10 alkyl, -OH, -OR 11 , -CH 2 OH, -CH 2 OR 11 , -CH 2 OC(O)R 21 wherein R 21 is C 1 to C 10 alkyl, -CH 2 0C(0)CH(R 22 )(NHRz 3 ) wherein R 22 is the side chain of any of the naturally occuring amino acids and R 23 is hydrogen or -C(O)CH(R 24 )(NH 2 ) wherein R 24 . is the side chain of any of the naturally occuring amino acids, -CH 2 SH, -CH 2 CI, -CH 2 F, -CH 2 Br, -CH 2 I, -C(O)H, -CH 2 CN, -CH 2 N 3 , -CH 2 NR 12 R 2 , -CO 2 R 1 , -CH 2 CH 2 0H, -CH 2 CH 2 OR 11 , -CH 2 CH 2 OC(O)R 21 wherein R 21 is as defined above, -CH 2 CH 2 OC(O)CH(R 22 ) (NHR 23 ) wherein R 22 and R 23 are as defined above, -CH 2 CH 2 PO 3 H 2 , -CH 2 OPO 3 H 2 , -CH 2 PO 3 H 2 , -OCH 2 PO 3 H 2 and -CH 2 CO 2 R 3 wherein R 2 is hydrogen, C 1 to C 10 alkyl or an N-protecting group, R 2 is hydrogen or C 1 to C 10 alkyl, R 3 is hydrogen, C 1 to C 10 alkyl, carboxyalkyl or aminoalkyl, R " is C 1 to C 6 alkyl or a hydroxy protecting group, and R 13 is an N-protecting group; and T is hydrogen, C 1 to C 10 alkyl, 2-haloethyl, halomethyl, difluoromethyl, trifluoromethyl, halogen, cyano, nitro, vinyl, 2-halovinyl, alkynyl, hydroxmethyl, formyl, azidomethyl, 2-hydroxyethyl, -NR 12 R 2 wherein R 12 and R 2 are as defined above, -NHOH, -SH, propenyl, 3,3,3-trifluoropropenyl, 2-(alkoxycarbonyl)ethenyl, 2-cyanoethenyl, wherein m is 1 to 5, or -CH 2 NR 12 R 2 wherein R 12 and R 2 are as defined above; with the proviso that when E is -OH then D is not -OH.

Claim 38

A process for the preparation of 9-(2 ,3 -Bis(hydroxymethyl)cyclobutyl)guanine comprising a) reacting 2-amino-6-chloropurine with a compound of the formula wherein X is a leaving group and R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl; b) reducing the resultant product to the bis-hydroxymethyl derivative and c) hydrolyzing to provide 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine.

Claim 39

A process for the preparation of 9-(2 ,3 -Bis(hydroxymethyl)cyclobutyl)guanine comprising a) reacting 2-amino-6-chloropurine with a compound of the formula wherein X is a leaving group and R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl; b) reducing the resultant product to the bis-hydroxymethyl derivative and c) hydrolyzing to provide 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine.

Claim 40

The process of Claim 22 wherein X is a halide, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, acetate, arylsulfonate or aalkylsulfonate and R 28 and R 29 are indepedently selected from loweralkyl.

Claim 41

A process for the preparation of a 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine comprising a) reacting 2-amino-6-chloropurine with a compound of the formula wherein R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl; b) reducing the resulting product to obtain the bis-hydroxymethyl derivative; and c) hydrolyzing to provide 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine.

Claim 42

A process for the preparation of a 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine comprising a) reacting 2-amino-6-chloropurine with a compound of the formula wherein R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl; b) reducing the resulting product to obtain the bis-hydroxymethyl derivative; and c) hydrolyzing to provide 9-(2',3'-Bis(hydroxymethyl)cyclobutyl)guanine.

Claim 43

A process for the preparation of a compound of the formula wherein X is halide, alkylsulfide or arylsulfide and R 28 and -R 29 are independently selected from loweralkyl, aryl and arylalkyl comprising a) reacting a compound of the formula CH2 = CH-X' with a dialkyl ester of fumaric or maleic acid in the presence of a catalyst or b) reacting a compound of the formula CH 2 = CH-X' with maleic anhydride in the presence of a catalyst followed by hydrolysis and esterification.

Claim 44

A process for the preparation of a compound of the formula wherein X is halide, alkylsulfide or arylsulfide and R 28 and -R 29 are independently selected from loweralkyl, aryl and arylalkyl comprising a) reacting a compound of the formula CH2 = CH-X' with a dialkyl ester of fumaric or maleic acid in the presence of a catalyst or b) reacting a compound of the formula CH 2 = CH-X' with maleic anhydride in the presence of a catalyst followed by hydrolysis and esterification.

Claim 45

A process for the preparation of a compound of the formula wherein X is halide, alkylsulfide or arylsulfide and R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl comprising reacting a compound of the formula CH 2 = CH-X' with maleic anhydride in the presence of a ultraviolet light followed by hydrolysis and esterification.

Claim 46

A process for the preparation of a compound of the formula wherein X is halide, alkylsulfide or arylsulfide and R 28 and R 29 are independently selected from loweralkyl, aryl and arylalkyl comprising reacting a compound of the formula CH 2 = CH-X' with maleic anhydride in the presence of a ultraviolet light followed by hydrolysis and esterification.